Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7798 and [11C]AZ14132516 PET Study in Crohn's Disease
NCT06432764Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd7798 in Crohn's disease, sponsored by AstraZeneca. Primary endpoint: Standardized Uptake Value / Standardized Uptake Value Ratio at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06432764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06432764.